Earlier this week, Harmony Biosciences (HRMY) pre-announced 2024 preliminary net revenue from WAKIX, its lead product, which is FDA-approved in type 1 and type 2 narcolepsy, and provided 2025 revenue guidance, H.C. Wainwright analyst Patrick Trucchio tells investors in a research note. Harmony expects Q4 net product revenues in line with the firm’s estimate and consensus, and announced 2025 net product revenue guidance $820M-$860M, on-track to a potential blockbuster opportunity, the firm says. H.C. Wainwright views Harmony shares as “highly attractive” at current levels with a cash generating franchise in WAKIX and an underappreciated pipeline.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio